Yale 2019-nCoV SalivaDirect ValuPanel Reagents

Yale 2019-nCoV SalivaDirect™ ValuPanel™ Reagents are now part of our ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures target the SARS-CoV-2 virus that causes COVID-19. For Research Use Only. Not for use in diagnostic procedures.

Key benefits

• Fast delivery: Product in stock ships same or next business day
• Gold standard quencher: From the trusted inventor and original source of Black Hole Quencher™ (BHQ™) technology referenced in 7 of 8 WHO protocols
• Quality manufacture: All probes and primers are HPLC purified and are manufactured and shipped from a facility entirely separate from positive control production.

order now in the
new transaction portal

The Yale 2019-nCoV SalivaDirect™ ValuPanel Reagents™ include FAM-BHQ and Quasar™ 670-BHQ probes and primers delivered in individual tubes in dried format. The oligonucleotide sequences were designed by US Centers for Disease Control and Prevention for use in real-time RT-PCR to detect SARS-CoV-2 viral strains.

The panel contains probes and primers comprising the following genetic signatures:

• SARS-CoV-2 N1 Primers (Forward and Reverse)
• SARS-CoV-2 N1 Probe
• Human RNase P Primers (Forward and Reverse)
• Human RNase P Probe (Quasar 670, SalivaDirect specific)

SalivaDirect is a protocol, developed by the Yale School of Public Health, for testing people suspected of SARS-CoV-2 infection. While the method still relies on RT-qPCR, it uses saliva samples instead of nasopharyngeal swabs. SalivaDirect was issued an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on August 15, 2020.

Learn more about SalivaDirect and how to apply to become a SalivaDirect-authorized lab. You can also view the full protocol on Protocols.io.

Each reaction requires the following:

• N1 forward and reverse primers: 400 nM/reaction
• N1 probe: 200 nM/reaction
• RNase P forward and reverse primers: 150 nM/reaction
• RNase P probe: 200 nM/reaction

order now in the
new transaction portal

PCR reagents* including master mix and enzyme for SARS-CoV-2 assay development are also available

For a complete SARS-CoV-2 Quality Solution, consider the AccuPlex™ SARS-CoV-2 Verification Panel coupled with the AccuPlex™ SARS-CoV-2 Reference Material Kit from LGC SeraCare Life Sciences. The target sequence of interest is packaged into a stable non-infectious, and replication-deficient alphavirus particle and the products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Also includes negative materials targeting the human RNase P gene.

*For Research Use Only. Not for use in diagnostic procedures.